VIS's QbD Approach and Innovative Drug Delivery Systems for Antisense Oligonucleotides

Mr. Shingo Nakamura

Representative Director, Founder and CEO

Veritas In Silico Inc.

Veritas In Silico Inc., whose primary business is developing small molecule drugs targeting mRNA, has begun applying its technology to nucleic acid-based drug discovery. We present the latest developments in our joint project with Mitsubishi Gas Chemical Company, Inc., approached from a Quality by Design （QbD） perspective, and introduce an innovative drug delivery system (DDS) that fundamentally resolves challenges in nucleic acid therapeutics. This DDS enables delivery with unprecedented precision—such as to either the left or right kidney, or a specific part of the lung—previously unthinkable.

Ms. Juran Kato

President & CEO

GEXVal Inc.

GEXVal is advancing rare disease drug development by unlocking the hidden value of drug candidates through our AI-driven drug discovery platform, RePhaIND®, using graph-attention autoencoder. We have completed an Australian Phase 1 trial including confirmation of target engagement, demonstrating an efficient global development model. By integrating AI-driven discovery approaches, we are practicing "Circular Economy in Drug Discovery" to deliver innovative life-changing medicines that patients and their families truly need. This presentation showcases our lead development program as a case study, illustrating our strategic approach to addressing critical unmet medical needs in rare diseases and beyond through sustainable drug development practices.

Small-Molecule Drug Discovery Strategy of the RaQualia Pharma Group and the Construction of an Early Out-Licensing-Driven Value Chain

Mr. Katsuhiro Uto

Board Director

RaQualia Pharma Inc.

RaQualia Pharma focuses on small-molecule drug discovery and has expanded its modality into Targeted Protein Degradation (TPD) through the acquisition of FIMECS into the group. This presentation outlines our strategy of early out-licensing and the construction of an open-innovation–driven drug discovery and development value chain. I will also summarize the key technical and industrial challenges in small-molecule drug discovery and TPD, as well as future perspectives for these modalities.